Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Gastroenterology · Gastrinoma

Treatment Strategies: Managing Acid and the Tumor

At a Glance

Gastrinoma treatment has two goals: control excess stomach acid with high-dose proton pump inhibitors and manage the tumor with surgery, surveillance, or tumor-directed therapy. The plan depends on whether disease is sporadic, MEN1-related, or metastatic.

Treating a gastrinoma involves two parallel goals that happen at the same time: protecting your digestive system from excess acid and managing the tumor itself [1][2]. Because gastrinomas are rare, specialized guidelines from groups like the NCCN (National Comprehensive Cancer Network) and ENETS (European Neuroendocrine Tumor Society) recommend a strategy tailored to whether your disease is sporadic or part of the MEN1 genetic syndrome [3][4]. Recommendations may differ slightly among specialist centers because management is highly individualized.

Goal 1: Controlling the Acid

The most immediate priority is stopping the massive overproduction of stomach acid that causes painful ulcers and diarrhea [1].

  • High-Dose PPIs: These are the “gold standard” of care [2]. You will likely be prescribed much higher doses of Proton Pump Inhibitors (PPIs) than someone with standard reflux [5].
  • Do Not Self-Adjust: You must never stop or change your PPI abruptly on your own. Doing so can cause a “rebound” of acid so severe it can lead to emergency bleeding or a perforated ulcer [2][6]. While some patients may eventually reduce their dose after successful surgery, tapering must be directed by your treating team.
  • Long-Term Monitoring: Because ZES often requires high-dose PPIs for years, your doctor may monitor you for individualized side effects like Vitamin B12 deficiency or low magnesium levels [6][7].

Goal 2: Managing the Tumor

Once the acid is stable, your care team turns its attention to the tumor. The path forward depends on your diagnosis type, tumor burden, and overall health:

The Sporadic Strategy (Localized Disease)

If your gastrinoma is “sporadic” (not genetic) and hasn’t spread widely, the goal is often curative-intent surgery [8].

  • The Procedure: Surgeons typically explore the gastrinoma triangle (the area where most of these tumors hide) to remove the primary mass and nearby lymph nodes [1][8]. Major surgery has substantial risks, including pancreatic or bile leaks, delayed gastric emptying, and digestive changes.
  • Outcome: For many patients with localized sporadic disease, this surgery can stop the excess gastrin production entirely [9].

The MEN1 Strategy (Genetic Syndrome)

Because MEN1 often involves many tiny tumors throughout the duodenum rather than one single mass, surgery is a more selective, individualized multidisciplinary decision [4].

  • Active Surveillance: If tumors are smaller than 2 cm and not growing rapidly, many experts recommend “watchful waiting” or active surveillance while managing acid with medication [10][11].
  • Surgery: Operation is usually considered for tumors that grow larger than 2 cm, show aggressive features, or cause structural problems [10]. The goal is to prevent spread while preserving as much healthy pancreas as possible to avoid diabetes or digestive enzyme loss [12][13].

Options for Advanced or Spread (Metastatic) Disease

If the tumor has spread (most commonly to the liver), treatment shifts to controlling the growth of these cells [14]. These therapies are not interchangeable; the choice depends on your tumor’s grade and receptor status.

  • Liver-Directed Therapies: If metastases are dominant in the liver, options like surgical resection or ablation may be used.
  • Somatostatin Analogs (SSAs): Medications like octreotide or lanreotide target receptors on the tumor’s surface to slow its growth [3]. While they can help reduce gastrin slightly, they are not a replacement for your acid-blocking PPIs [3][15].
  • PRRT (Peptide Receptor Radionuclide Therapy): This is a form of “liquid radiation” given through an IV. It uses a molecule that seeks out the tumor and delivers radiation directly to it [16]. Research shows PRRT can lead to a “clinical response” in many patients with advanced gastrinomas [16]. Proactive high-dose PPIs are often used during PRRT to prevent digestive flare-ups during treatment [17].
  • Targeted Therapies: For more aggressive or progressing cases, medications like everolimus or sunitinib, or even specialized chemotherapy, may be used to block the pathways the tumor uses to grow [18][19].

Summary of the Decision Tree

If your disease is… The primary approach is often…
Sporadic & Localized Curative-intent surgery (resection + lymphadenectomy) [8].
MEN1-Related Active surveillance and acid control, unless a tumor reaches surgical thresholds (often 2 cm) [10].
Metastatic (Spread) Systemic therapy (SSAs, PRRT, targeted drugs) or liver-directed therapies + acid control [3][16].

Common questions in this guide

What treatment is usually started first for a gastrinoma?
High-dose proton pump inhibitors, or PPIs, are usually started to control the excess stomach acid that causes ulcers and diarrhea. The dose is often higher than the dose used for ordinary reflux. Never stop or change a PPI suddenly because acid can return severely and cause bleeding or a perforated ulcer.
Can surgery cure a localized sporadic gastrinoma?
When a sporadic gastrinoma has not spread widely, surgeons often use curative-intent surgery to remove the tumor and nearby lymph nodes. The operation may include an exploration of the gastrinoma triangle, where many of these tumors are found. Surgery can stop excess gastrin production in many patients, but it may cause pancreatic or bile leaks, delayed stomach emptying, or digestive changes.
How is a gastrinoma linked to MEN1 treated?
MEN1 can cause multiple small gastrinomas, especially in the duodenum, so treatment is individualized. Tumors smaller than 2 centimeters that are not growing quickly may be monitored while acid is controlled with medication. Surgery is more often considered when tumors grow beyond 2 centimeters, show aggressive features, or cause structural problems.
What treatments are available if a gastrinoma has spread?
For metastatic gastrinoma, treatment may include surgery or ablation directed at liver metastases, medicines such as octreotide or lanreotide, peptide receptor radionuclide therapy, targeted drugs, or chemotherapy. The choice depends on how fast the tumor is growing, its grade, and whether it has the receptors needed for certain treatments. Acid suppression with a PPI usually remains important even when tumor-directed therapy is added.
Do octreotide and lanreotide replace acid-blocking medicine?
No. Octreotide and lanreotide may slow tumor growth and can modestly reduce gastrin, but they are not substitutes for the PPI used to control the stomach's excess acid. Your treatment team should decide whether both types of medicine are needed.
What should be monitored during long-term high-dose PPI treatment?
People who need high-dose PPIs for a long time may need individualized monitoring for low vitamin B12 or magnesium levels. Your clinician may recommend blood tests based on your treatment duration, health history, and symptoms. Do not reduce or stop the PPI on your own to avoid rebound acid and serious complications.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my tumor have 'somatostatin receptors' on its surface, and am I a candidate for PRRT if my disease progresses?
  2. 2.What are the specific symptoms that would prompt us to monitor my magnesium or vitamin B12 levels while on long-term PPIs?
  3. 3.If I have sporadic disease, does your surgical team plan to perform a full exploration of the 'gastrinoma triangle' and a lymphadenectomy?
  4. 4.For my MEN1-related case, what specific changes in tumor size or growth rate would trigger a shift from monitoring to surgery?
  5. 5.How often will we perform follow-up imaging (like DOTATATE PET or MRI) to monitor my tumor's response to treatment?
  6. 6.If I begin Somatostatin Analogs (SSAs), will we still need to monitor my gastric acid output to ensure my PPI dose is adequate?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update.

    Chatzipanagiotou O, Schizas D, Vailas M, et al.

    Journal of neuroendocrinology 2023; (35(4)):e13267 doi:10.1111/jne.13267.

    PMID: 37042078
  2. 2

    Assessing for Multiple Endocrine Neoplasia Type 1 in Patients Evaluated for Zollinger-Ellison Syndrome-Clues to a Safer Diagnostic Process.

    Singh Ospina N, Donegan D, Rodriguez-Gutierrez R, et al.

    The American journal of medicine 2017; (130(5)):603-605 doi:10.1016/j.amjmed.2016.11.035.

    PMID: 28011308
  3. 3

    The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

    Guarnotta V, Martini C, Davì MV, et al.

    Endocrine 2018; (60(1)):15-27 doi:10.1007/s12020-017-1420-4.

    PMID: 29019150
  4. 4

    How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?

    Imamura M, Komoto I, Taki Y

    Surgery today 2023; (53(12)):1325-1334 doi:10.1007/s00595-022-02627-z.

    PMID: 36473964
  5. 5

    Diagnostic and Treatment Approaches for Refractory Peptic Ulcers.

    Kim HU

    Clinical endoscopy 2015; (48(4)):285-90 doi:10.5946/ce.2015.48.4.285.

    PMID: 26240800
  6. 6

    Total gastrectomy for severe proton pump inhibitor-induced hypomagnesemia in a MEN1/Zollinger Ellison syndrome patient.

    Perrier M, Delemer B, Deguelte S, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021; (21(1)):236-239 doi:10.1016/j.pan.2020.12.002.

    PMID: 33309626
  7. 7

    Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.

    Maideen NMP

    Chonnam medical journal 2023; (59(2)):115-127 doi:10.4068/cmj.2023.59.2.115.

    PMID: 37303818
  8. 8

    Recurrence after surgical resection of nonmetastatic sporadic gastrinoma: Which prognostic factors and surgical procedure?

    Robin L, Sauvanet A, Walter T, et al.

    Surgery 2023; (173(5)):1144-1152 doi:10.1016/j.surg.2022.12.030.

    PMID: 36781315
  9. 9

    Gastrinomas: Medical or Surgical Treatment.

    Norton JA, Foster DS, Ito T, Jensen RT

    Endocrinology and metabolism clinics of North America 2018; (47(3)):577-601 doi:10.1016/j.ecl.2018.04.009.

    PMID: 30098717
  10. 10

    Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies.

    Shao QQ, Zhao BB, Dong LB, et al.

    World journal of gastroenterology 2019; (25(32)):4673-4681 doi:10.3748/wjg.v25.i32.4673.

    PMID: 31528093
  11. 11

    Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).

    van Beek DJ, Nell S, Pieterman CRC, et al.

    Journal of surgical oncology 2019; (120(6)):966-975 doi:10.1002/jso.25667.

    PMID: 31401809
  12. 12

    Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1.

    Kong W, Albers MB, Manoharan J, et al.

    Cancers 2022; (14(8)) doi:10.3390/cancers14081928.

    PMID: 35454834
  13. 13

    Results of Duodenopancreatic Reoperations in Multiple Endocrine Neoplasia Type 1.

    Albers MB, Manoharan J, Bollmann C, et al.

    World journal of surgery 2019; (43(2)):552-558 doi:10.1007/s00268-018-4809-1.

    PMID: 30288555
  14. 14

    Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study.

    Massironi S, Cavalcoli F, Elvevi A, et al.

    Endocrine 2022; (75(3)):942-948 doi:10.1007/s12020-021-02915-7.

    PMID: 34716542
  15. 15

    Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.

    Rossi RE, Elvevi A, Citterio D, et al.

    World journal of gastroenterology 2021; (27(35)):5890-5907 doi:10.3748/wjg.v27.i35.5890.

    PMID: 34629807
  16. 16

    Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma.

    Dumont RA, Seiler D, Marincek N, et al.

    American journal of nuclear medicine and molecular imaging 2015; (5(1)):46-55.

    PMID: 25625026
  17. 17

    Case Report: PRRT in a patient with Zollinger-Ellison syndrome. The management of gastrointestinal complications.

    Di Franco M, Durmo R, Di Paolo ML, et al.

    Frontiers in oncology 2025; (15()):1590478 doi:10.3389/fonc.2025.1590478.

    PMID: 40458720
  18. 18

    (68)Ga-DOTATOC-PET/CT for effective diagnosis and treatment of pancreatic tail gastrinoma with multiple liver metastases: a case report.

    Matsumura S, Okuyama Y, Doi R, et al.

    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 2016; (113(1)):86-93 doi:10.11405/nisshoshi.113.86.

    PMID: 26743558
  19. 19

    Management of functional neuroendocrine tumors of the pancreas.

    Öberg K

    Gland surgery 2018; (7(1)):20-27 doi:10.21037/gs.2017.10.08.

    PMID: 29629316

This page explains gastrinoma treatment options for informational purposes only and does not constitute medical advice. Do not change or stop your PPI without guidance from your treating team; discuss surgery, surveillance, and tumor-directed treatments with your specialists.

Get notified when new evidence is published on pancreatic gastrinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.